We are live on ! Find out more
APEN

Apollo Endosurgery, Inc.

Delisted

APEN was delisted on the 3rd of April, 2023.

89 hedge funds and large institutions have $442M invested in Apollo Endosurgery, Inc. in 2023 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

73,045% more call options, than puts

Call options by funds: $21.2M | Put options by funds: $29K

65% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 20

45% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 20

20% more capital invested

Capital invested by funds: $368M → $442M (+$74M)

13% more funds holding in top 10

Funds holding in top 10: 89 (+1)

11% more funds holding

Funds holding: 8089 (+9)

Holders
89
Holders Change
+9
Holders Change %
+11.25%
% of All Funds
1.42%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.14%
New
29
Increased
33
Reduced
20
Closed
20
Calls
$21.2M
Puts
$29K
Net Calls
+$21.2M
Net Calls Change
-$12.5M

APEN Hedge Fund Activity: Q1 2023 in Review

89 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Apollo Endosurgery, Inc. (APEN) for Q1 2023, worth a combined $442M — up 20% from $368M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new APEN positions and 20 closed out — a net gain of 9 holders — while 33 added to existing stakes and 20 trimmed.

The largest buyer was Nexpoint Asset Management, adding an estimated $35.7M. The largest seller was Stonepine Capital Management, cutting an estimated $33.2M.

  • 89 institutional investors held Apollo Endosurgery, Inc. (APEN) as of Q1 2023, up from 80 in Q4 2022.
  • Funds reported $442M of Apollo Endosurgery, Inc. stock for Q1 2023, up 20% quarter-over-quarter.
  • 29 funds opened new Apollo Endosurgery, Inc. positions in Q1 2023 and 20 closed out, a net change of +9 holders.
  • The largest Apollo Endosurgery, Inc. buyer in Q1 2023 was Nexpoint Asset Management, an estimated $35.7M added.
  • The largest Apollo Endosurgery, Inc. seller in Q1 2023 was Stonepine Capital Management, an estimated $33.2M sold.

Based on aggregated 13F filings for Q1 2023.